H. Küpper

7.7k total citations · 2 hit papers
127 papers, 5.8k citations indexed

About

H. Küpper is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, H. Küpper has authored 127 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Rheumatology, 59 papers in Hematology and 32 papers in Genetics. Recurrent topics in H. Küpper's work include Rheumatoid Arthritis Research and Therapies (71 papers), Autoimmune and Inflammatory Disorders Research (56 papers) and Chronic Lymphocytic Leukemia Research (30 papers). H. Küpper is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (71 papers), Autoimmune and Inflammatory Disorders Research (56 papers) and Chronic Lymphocytic Leukemia Research (30 papers). H. Küpper collaborates with scholars based in Germany, United States and Netherlands. H. Küpper's co-authors include Robert Wong, Désirée van der Heijde, Joachim Sieper, S. Kary, Martín Rudwaleit, Jürgen Braun, Alan Kivitz, Maxime Dougados, John C. Davis and Martina Kron and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and Critical Care Medicine.

In The Last Decade

H. Küpper

118 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

2006 660 citations Désirée van der Heijde, Michael Schiff et al. Arthritis & Rheumatism profile →
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

2004 512 citations L.B.A. van de Putte, Catherine Atkin et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Küpper Germany	37	4.5k	2.4k	2.0k	527	457	127	5.8k
Antonio Marchesoni Italy	37	5.2k 1.2×	3.6k 1.5×	2.3k 1.1×	345 0.7×	379 0.8×	144	6.4k
Kath Watson United Kingdom	37	3.6k 0.8×	1.6k 0.7×	1.4k 0.7×	723 1.4×	583 1.3×	79	5.8k
E. Martín‐Mola Spain	44	4.2k 0.9×	1.6k 0.7×	1.5k 0.7×	663 1.3×	281 0.6×	113	6.0k
Raimón Sanmartí Spain	40	3.6k 0.8×	1.6k 0.7×	1.3k 0.6×	416 0.8×	385 0.8×	263	5.3k
Ronald Pedersen United States	27	3.4k 0.8×	1.3k 0.6×	1.7k 0.8×	694 1.3×	266 0.6×	66	4.7k
R. B. M. Landewé Netherlands	22	5.0k 1.1×	2.1k 0.9×	1.8k 0.9×	284 0.5×	232 0.5×	65	5.7k
Xavier Le Loët France	42	3.3k 0.7×	1.4k 0.6×	1.3k 0.6×	644 1.2×	371 0.8×	198	5.4k
Alfons A den Broeder Netherlands	39	3.5k 0.8×	1.3k 0.5×	966 0.5×	577 1.1×	242 0.5×	225	5.0k
Elliot Chartash United States	23	3.0k 0.7×	1.4k 0.6×	1.5k 0.7×	601 1.1×	259 0.6×	49	4.7k
Bruce Kirkham United Kingdom	38	4.1k 0.9×	3.9k 1.6×	2.1k 1.0×	206 0.4×	354 0.8×	143	7.2k

Countries citing papers authored by H. Küpper

Since Specialization

Citations

This map shows the geographic impact of H. Küpper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Küpper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Küpper more than expected).

Fields of papers citing papers by H. Küpper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Küpper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Küpper. The network helps show where H. Küpper may publish in the future.

Co-authorship network of co-authors of H. Küpper

This figure shows the co-authorship network connecting the top 25 collaborators of H. Küpper. A scholar is included among the top collaborators of H. Küpper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Küpper. H. Küpper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

D’Cunha, Ronilda, H. Küpper, Dilek Arikan, et al.. (2023). A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants. British Journal of Clinical Pharmacology. 90(1). 189–199. 6 indexed citations

Buttgereit, Frank, Jacob Aelion, Bernadette Rojkovich, et al.. (2022). Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial. Arthritis & Rheumatology. 75(6). 879–889. 31 indexed citations

Yamanaka, Hisashi, Naoko Ishiguro, Tsutomu Takeuchi, et al.. (2014). Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Lara D. Veeken. 53(5). 904–913. 25 indexed citations

Smolen, Josef S, Paul Emery, Roy Fleischmann, et al.. (2013). Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. The Lancet. 383(9914). 321–332. 210 indexed citations

Keystone, E C, F. C. Breedveld, D. van der Heijde, et al.. (2013). Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial. Data Archiving and Networked Services (DANS). 65. 1 indexed citations

Imagawa, Tomoyuki, Syuji Takei, Hiroaki Umebayashi, et al.. (2012). Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clinical Rheumatology. 31(12). 1713–1721. 58 indexed citations

Breedveld, F. C., Edward Keystone, D. van der Heijde, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10). 118–119. 5 indexed citations

Keystone, Edward, D. van der Heijde, M. Weinblatt, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10). 1 indexed citations

Maksymowych, Walter P., Katherine Gooch, Maxime Dougados, et al.. (2010). Thresholds of patient‐reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics. Arthritis Care & Research. 62(6). 826–834. 33 indexed citations

10.

Rudwaleit, Martín, Filip Van den Bosch, Martina Kron, S. Kary, & H. Küpper. (2010). Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Research & Therapy. 12(3). R117–R117. 74 indexed citations

11.

Rudwaleit, Martín, Pascal Claudepierre, Martina Kron, et al.. (2010). Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Research & Therapy. 12(2). R43–R43. 27 indexed citations

12.

Heijde, Désirée van der, Ben A. C. Dijkmans, A. Kivitz, et al.. (2008). Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS). Oxford University Research Archive (ORA) (University of Oxford). 58. 2 indexed citations

13.

Bejarano, Victoria, Mark Quinn, Philip G. Conaghan, et al.. (2008). Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Care & Research. 59(10). 1467–1474. 136 indexed citations

14.

Wordsworth, P, et al.. (2007). Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira (R)) treatment. Lara D. Veeken. 46. 1 indexed citations

15.

Heijde, Désirée van der, A. Kivitz, Michael Schiff, et al.. (2006). Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.. Oxford University Research Archive (ORA) (University of Oxford). 54. 4 indexed citations

16.

Burmester, G. R., et al.. (2005). Efficacy and safety of adalimumab (Humira (R)) in European clinical practice: The ReAct trial. Lara D. Veeken. 44.

17.

Putte, L.B.A. van de, Catherine Atkin, Michel Malaise, et al.. (2004). Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the Rheumatic Diseases. 63(5). 508–516. 512 indexed citations breakdown →

18.

Reinhart, Konrad, T. Menges, Bengt Gårdlund, et al.. (2001). Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Critical Care Medicine. 29(4). 765–769. 180 indexed citations

19.

Putte, Leo van de, Piet L. C. M. van Riel, Alfons A den Broeder, et al.. (1998). A SINGLE DOSE PLACEBO CONTROLLED PHASE I STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS. Arthritis & Rheumatism. 41(9). 21 indexed citations

20.

Küpper, H., et al.. (1991). [Epitope analysis of CD68 antigens].. PubMed. 37(3-4). 175–81. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact